key: cord-0815739-m0fpqalk
authors: Bhattacharya, Deepanjan; Sambaturu, Vishwanatha Kartik; Harikrishnan, Kurup K.N.; Ajitkumar, V. K.
title: Inflammatory markers in COVID19, are they really specific? / Inflammatory markers in COVID19
date: 2021-12-31
journal: Indian Heart Journal
DOI: 10.1016/j.ihj.2021.11.104
sha: e6b89c2dcdbf4ae40a521b88e5fef5ed5e0ba5fa
doc_id: 815739
cord_uid: m0fpqalk

nan

Background: Ventricular septal rupture was once a common complication of myocardial infarction associated with poor outcome. It is significantly associated with poor outcome, and mortality rate has been reported to be 88-100%. There is lack of data from the Indian subcontinent regarding the outcome of VSR, and hence we analysed our cohort of patients over the last 10 years to look at outcomes and predictors of mortality. Methods and Results: This was a retrospective study carried out in the Department of Cardiology in a tertiary care teaching hospital in Southern India. All patients admitted with ventricular septal rupture from January 2010 to June 2020 were included. 52 patients were enrolled in the study, with a mean age of 64.8 years. Half were older than 65 years of age, and a slight male preponderance was seen (M:F 1.2:1). Anterior wall STEMI was association with 63.5% of cases while inferior wall STEMI was seen in onethird of cases. 13.5% underwent fibrinolysis, out of which streptokinase was the commonest modality used, while 29% underwent percutaneous coronary intervention. Hypertension and diabetes mellitus were the commonest co-morbidity, seen in half of the patients each. 6 patients had past history of coronary artery disease. Average size of ventricular septal defect was 11.6±5.7mm, while significant mitral and tricuspid regurgitation were seen in 32% and 42% of cases. More than half had anemia, while leucocytosis was seen in 75% of patients. Nearly all had elevated cardiac biomarkers and hepatic enzymes along with deranged renal function test seen in more than half. Multivessel CAD was seen in more than 70% and left anterior descending (LAD) being the commonest diseased vessel (90%). 22 patients underwent surgical repair, out of which 60% were operated after 14 th day of admission. Teflon and Dacron were the commonest materials used for repair. 5 patients underwent device closure using Amplatzer device occlude. There was no significant difference in mortality between device closure and surgical repair (60% vs 45.5%, p¼0.74).Mortality rate was 61.5%, with major predictors of death being older age, shorter duration of symptoms, ST elevation on ECG, elevated NT pro BNP, leucocytosis, alanine and aspartate transaminases, deranged renal function test, cardiogenic shock, acute kidney injury and need for IABP. 16 patients died within 7 days of hospitalisation, whereas 27 died within 30 days (7-day mortality: 30.7%, 30-day mortality 51.9%) Conclusion: Ventricular septal rupture, although uncommon in the early reperfusion era, is associated with significant mortality, which has reduced over the past decade. Older age, shorter duration of symptoms, leucocytosis, elevated hepatic transaminases, acute kidney injury, elevated NT-pro BNP, presence of cardiogenic shock and use of intra-aortic balloon pump were associated with increased mortality. Those who underwent surgical repair had a distinct survival advantage. Background: COVID19 infection is a recognized risk factor for systemic thrombosis. There have been few case reports about thrombosis following COVID19 vaccination. Methods and Results: A middle aged lady presented with acute pulmonary thromboembolism with right ventricular dysfunction and heart failure, with history of cerebral sinovenous thrombosis 3 weeks back. Thrombophilia workup and DVT screen was negative, but on reviewing history she had received CoviShield vaccine 1 week prior to the CSVT. She was thrombolysed which was unsuccessful, and then planned for mechanical thrombectomy but died prior to the procedure. Conclusion: COVID19 vaccine, especially those containing adenoviral particles, have an inherent predisposition to cause thrombosis by immune-mediated reactions. Although the risk is very less as compared to the benefit derived, it should be taken into account in patients who present with unexplained thrombosis post vaccination. Background: The novel coronavirus (COVID 19) has now progressed to cause a major pandemic infecting over 10 million people worldwide and resulting in over five hundred thousand deaths. Patients with co-morbidities like diabetes mellitus, coronary artery disease and hypertension are at increased risk with higher mortality rates. Various studies have found that elevated C-reactive protein, ferritin, d-dimer and procalcitonin levels associated with COVID19 infected patients. We analysed 100 patients admitted in our Department of Cardiology, for these inflammatory markers, all of whom were tested negative RT-PCR for COVID19. Methods and Results: We selected 100 consecutive patients who were admitted in our Cardiology Department either for management of acute cardiovascular ailment or for a elective or diagnostic procedure. All of them underwent reverse-transcriptase polymerase chain reaction (RT-PCR) for COVID19. Demographic details were noted, and blood sample of these patients were sent for estimation of serum ferritin, d-dimer, C-reactive protein, procalcitonin and lactate dehydrogenase. Data entry was done in Microsoft excel 2013 (Microsoft, Redmond, WA, USA) and statistical analysis was performed on SPSS software version 21. Comparative analysis was carried out using Chi-Square or Fisher's exact test for categorical variables and Student-t test for continuous variables. The p value <0.05 was considered significant. Over 70% of the study population were male individuals, while mean age was 58.2 years. Hypertension was the commonest co-morbidity followed by diabetes mellitus. When compared against those undergoing elective admissions, patients who were admitted in emergency settings had similar vitals at admission except for higher heart rate and lower diastolic blood pressure; there was no significant difference between laboratory parameters. We compared our results to the data published by Huang et al [2] , Liu et al [3] , Li et al [4] and Chen et al [5] in COVID19 positive patients, our patients had similar levels of procalcitonin, d-dimer and lactate dehydrogenase, in spite of being COVID19 negative. However ferritin and C-reactive protein were significantly lower than COVID19 positive patients. Conclusion: Hence, although elevation of these biomarkers should make the clinician suspect COVID19 infection in today's scenario, one should not be dogmatic about considering COVID19 as the only differential diagnosis in such a patient. 

Total 2000 patients (mean age: 54.45 years, 55.7% males) were enrolled. The most common comorbidity was diabetes (31.6%). Newly diagnosed and preexisting hypertension was reported in 47.85% and 52.15% patients respectively. Mean duration of pre-existing hypertension was 68.48 months. At diagnosis, combination therapy and monotherapy was prescribed in 33.94% (baseline BP 149.69/84.86 mmHg) and 66.06% (baseline BP 145.30/86.14 mmHg) of pre-existing patients respectively, whereas, in newly diagnosed patients combination therapy and monotherapy was prescribed in 56.74% (baseline BP 153.71/87.36 mmHg) and 43.26 % (baseline BP 146.53/85.83 mmHg) respectively. At enrolment, 56.66% patients were on combination therapy and 43.34% patients were on monotherapy in pre-existing patients. Amlodipine (36.14%) and Telmisartan (18.43%) were most common monotherapies, whereas Amlodipine + Telmisartan (19.77%) was most common combination therapy in pre-existing (at diagnosis) patients. In newly diagnosed patients, Telmisartan (43.72%) and Amlodipine (25.85%) were most common monotherapies, and Amlodipine + Telmisartan (42.73%) was most common combination therapy. In QoL assessment, physical and emotional role functioning, social functioning, and emotional well-being markedly improved at 1 year with both monotherapy and combination therapy. At diagnosis, in pre-existing patients with hypertension plus diabetes, Amlodipine (27.11%, n¼90) was most common monotherapy and Amlodipine + Telmisartan